Assessing the financial impact of Translational Pharmaceutics®

A white paper by the Tufts Center for the Study of Drug Development (CSDD) comparing the savings and financial benefits for drug developers that use Translational Pharmaceutics®

Unlock the multi-million dollar benefits of Translational Pharmaceutics®, demonstrated in the Tufts CSDD study

Discover the time savings and financial benefits for drug developers that use Translational Pharmaceutics®, versus traditional multi-vendor formulation, manufacturing and clinical testing approaches.

Download the white paper today!

We respect your privacy. Find out how we handle your personal information in our privacy policy.
Two scientists looking at an HBLC Machine in our Translational Pharmaceutics labs

What can I learn?

Discover how to benefit from:

  • A faster approach to drug development and accelerated time to market
  • Average timeline savings of >12 months
  • R&D spend reduced by $9.5 million for each month of time saved
  • Total financial gains per drug approved >$100 million
  • Formulations selected using clinical data, ensuring greater chances of success
  • An integrated development model and simplified supply chain

About Translational Pharmaceutics®

Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing, and clinical testing. Over the past decade, it has been used widely by pharmaceutical and biotech companies on >400 programs to advance molecules across the full development cycle, from first-in-human (FIH) trials to market. Key applications within the development process include:

  • Transitioning molecules from FIH to proof of concept (POC)
  • Development and optimization of clinical formulations

About the Tufts CSDD study

The Tufts CSDD compared the cycle times of traditional drug development programs to Translational Pharmaceutics® programs and their derivative effects on development economics. These data were incorporated in a drug development model and the financial benefits were quantified on industry R&D costs and returns. The model assessed several different project types and the top line results included mean financial benefits exceeding $100 million and mean timeline savings of >12 months.

Ready to accelerate your drug development program? Discover our uniqiue platform,
Translational Pharmaceutics®